Article
Genetics & Heredity
Fangshu Liu, Suqi Deng, Yue Li, Juan Du, Hui Zeng
Summary: In this study, the researchers found that the high expression level of SLC25A1 gene in AML patients is associated with unfavorable prognosis. They further demonstrated that inhibition of SLC25A1 can inhibit the proliferation and increase the apoptosis of AML cells. By constructing a SLC25A1-associated gene panel, they established a prognostic risk-scoring model that can be used as an independent biomarker to assess prognosis in AML.
FRONTIERS IN GENETICS
(2023)
Article
Biochemistry & Molecular Biology
Huiqing Qu, Ye Zhu
Summary: The study revealed that SMPDL3B expression is upregulated in AML patients and is associated with poor clinicopathologic characteristics and overall survival. Inhibiting SMPDL3B expression can suppress AML cell growth by promoting apoptosis.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Genetics & Heredity
Zhihong Ren, Xiaoyu Huang, Qing Lv, Yiming Lei, Haiqiang Shi, Fanping Wang, Mingyong Wang
Summary: B4GALT1 is overexpressed and plays a vital role in the occurrence of acute myeloid leukemia (AML). It has reference value in the diagnostic and prognostic assessment of AML. B4GALT1-related genes are closely associated with negative regulation of the apoptotic signaling pathway, and silencing B4GALT1 promotes apoptosis. Additionally, B4GALT1 expression is correlated with the infiltration levels of different immune cells.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Zhengwei Wu, Jiawang Ou, Nannan Liu, Zhixiang Wang, Junjie Chen, Zihong Cai, Xiaoli Liu, Xiao Yu, Min Dai, Hongsheng Zhou
Summary: This study found that the expression level of T-cell immunoglobulin mucin-3 (Tim-3) on leukemia stem cells (LSC) is associated with prognosis in acute myeloid leukemia (AML), with high Tim-3 expression linked to poor overall survival and disease-free survival. Additionally, the upregulation of Tim-3 is associated with immune response, cell adhesion molecules, and signaling pathways.
Article
Oncology
Alexander Michael Grandits, Chi Huu Nguyen, Angela Schlerka, Hubert Hackl, Heinz Sill, Julia Etzler, Elizabeth Heyes, Dagmar Stoiber, Florian Grebien, Gerwin Heller, Rotraud Wieser
Summary: Despite the approval of targeted drugs for AML therapy, chemotherapy remains important. Low expression of MTSS1 is associated with poor prognosis in AML, regulated by promoter methylation and reduced by cytosine arabinoside and daunorubicin. Experimental downregulation of MTSS1 affects expression of numerous genes and increases resistance to chemotherapy.
Article
Oncology
Henan Zhang, Yue Zhao, Xuan Liu, Yusi Liu, Xiaohui Wang, Yu Fu, Shuang Fu, Jihong Zhang
Summary: The upregulated AC026150.8 in AML is associated with poor prognosis, high leukocyte counts, FAB classification, MLL-AF9 expression, and NPM1 mutations. Upregulation of AC026150.8 increases drug resistance in AML cells and can interact with the splicing factor PCBP1. Further studies on AC026150.8 and its downstream target genes are needed to elucidate its mechanism in AML.
Article
Oncology
Chaofeng Liang, Yujie Zhao, Cunte Chen, Shuxin Huang, Tairan Deng, Xiangbo Zeng, Jiaxiong Tan, Xianfeng Zha, Shaohua Chen, Yangqiu Li
Summary: Higher expression of TOX genes is associated with poor overall survival in AML patients and is related to the up-regulation of immune checkpoint genes. These findings provide new predictors for AML outcomes and direction for further research on the potential use of TOX genes in novel targeted therapies for AML.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Shuang Li, Guangjie Zhao, Wanling Wu, Nianyi Li, Qian Wang, Wei Wang, Xianmin Song, Xiaoqin Wang
Summary: This study found that circular RNAs play important regulatory roles in myelodysplastic syndromes and acute myeloid leukemia and are associated with clinical parameters and survival rates of the diseases.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Review
Medicine, General & Internal
Dirk Reinhardt, Evangelia Antoniou, Katharina Waack
Summary: This review discusses the key developments in pediatric acute myeloid leukemia (AML) in terms of diagnosis, treatment, risk groups, and outcomes. It also provides a brief overview of current and future approaches.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Junlin Zhang, Liying Liu, Jinshuang Wei, Xiaojing Wu, Jianming Luo, Hongying Wei, Liao Ning, Yunyan He
Summary: Through transcriptomics analysis of mRNA data from 27 children with non-M3 AML, biomarkers associated with AML prognosis were identified. Enrichment analysis revealed two modules correlated with AML risk groups. Further analysis using TCGA data identified four significant genes, including FTH1, as key factors associated with AML prognosis. Experimental findings confirmed that high expression of FTH1 promoted cell proliferation and inhibited apoptosis in leukemia cells through the ferroptosis pathway, highlighting its potential as a risk factor affecting non-M3 AML prognosis in children.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Hao Xiong, Xinwen Zhang, Xiaomin Chen, Yang Liu, Jialin Duan, Chunlan Huang
Summary: The study revealed that high expression of ISG20 serves as a poor prognostic indicator in AML patients, being related to overall survival time.
Review
Biochemistry & Molecular Biology
Daniela Damiani, Mario Tiribelli
Summary: The prognosis of acute myeloid leukemia (AML) remains unsatisfactory due to poor response to therapy or relapse, which can be attributed to the over-expression of multidrug resistance (MDR) proteins. ABCG2, an efflux transporter responsible for inducing MDR in leukemic cells, has the ability to extrude many antineoplastic drugs, leading to AML resistance and/or relapse. This review focuses on the expression and role of ABCG2, as well as its regulation and potential inhibition to counteract drug resistance and improve outcomes in AML patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Fangmin Zhong, Fangyi Yao, Ying Cheng, Jing Liu, Nan Zhang, Shuqi Li, Meiyong Li, Bo Huang, Xiaozhong Wang
Summary: The study identified m(6)A-related lncRNAs through correlation analysis and investigated their roles and prognostic value in AML. The findings suggest that m(6)A-related lncRNAs, evaluated using a risk prediction model, can potentially predict prognosis and design immunotherapy for AML patients.
SCIENTIFIC REPORTS
(2022)
Article
Pharmacology & Pharmacy
Cunte Chen, Ling Xu, Rili Gao, Shunqing Wang, Yuping Zhang, Caixia Wang, Chengwu Zeng, Yangqiu Li
Summary: The study revealed that increased BRD4 expression was associated with poor overall survival in AML patients. Additionally, co-expression of BRD4 with PD-1 or PD-L1 was linked to worse overall survival. The co-expression of BRD4 and PD-L1 was positively correlated with high tumor mutation burden and contributed to poor overall survival in AML patients.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Flavia Melo Cunha de Pinho Pessoa, Caio Bezerra Machado, Igor Valentim Barreto, Giulia Freire Sampaio, Deivide de Sousa Oliveira, Rodrigo Monteiro Ribeiro, Germison Silva Lopes, Maria Elisabete Amaral de Moraes, Manoel Odorico de Moraes Filho, Lucas Eduardo Botelho de Souza, Andre Salim Khayat, Caroline Aquino Moreira-Nunes
Summary: Acute myeloid leukemia (AML) is a blood cancer caused by genetic mutations, chromosomal translocations, or molecular changes. These alterations accumulate in stem cells and progenitor cells, leading to the development of AML, which is prevalent in 80% of adult acute leukemias. Recurrent cytogenetic abnormalities serve as diagnostic and prognostic markers and also confer resistance to traditional treatments. Immunophenotyping can help characterize the surface antigens of AML cells, aiding in the understanding of their molecular and immunophenotypic alterations.